Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Research Progress on Fumonisin B1 Contamination and Toxicity: A Review

Jia Chen, Jun Wen, Yating Tang and 5 more

Molecules · 2021 · Review · CC BY

doi:10.3390/molecules26175238

Abstract

Fumonisin B1 (FB1), belonging to the member of fumonisins, is one of the most toxic mycotoxins produced mainly by Fusarium proliferatum and Fusarium verticillioide. FB1 has caused extensive contamination worldwide, mainly in corn, rice, wheat, and their products, while it also poses a health risk and is toxic to animals and human. It has been shown to cause oxidative stress, endoplasmic reticulum stress, cellular autophagy, and apoptosis. This review focuses on the current stage of FB1 contamination, its toxic effects of acute toxicity, immunotoxicity, organ toxicity, and reproductive toxicity on animals and humans. The potential toxic mechanisms of FB1 are discussed. One of the main aims of the work is to provide a reliable reference strategy for understanding the occurrence and toxicity of FB1.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Fumonisins (FUMs) are mycotoxins produced from Fusarium spp. Among them, the amount of fumonisins produced by Fusarium verticilliodes and Fusarium proliferatum is the most pronounced. In many countries, fumonisin B1 (FB1) is produced by Gibberella fujikuroi var. moniliformis (Fusarium verticillioides). It was first isolated from Fusarium moniliforme MRC 826 in 1988 by South African scientist Gelderblom et al.. In the same year the structure of fumonisin was detected by mass spectrometry and 1H and 13C n.m.r. The structure of fumonisins is similar to that of sphingolipids, with the main chain containing 19–20 carbon atoms and the rest of the various groups distributed on both sides of the main chain (Figure 1). So far, Fumonisins are classified into four major groups, FA, FB, FC, and FP, depending on the type of moiety. Among them, FB1, FB2, and FB3 are most frequently found in food and often occur together in a ratio of approximately 68:20:12. FB1 is the most abundant and toxic, posing the greatest threat to animal and human health, and most scholars are conducting research on FB1. Fumonisin B1 is a water-soluble mycotoxin that is stable to heat, and its chemical structure is shown in Figure 1. Animal ingestion of FB1-containing feed can cause a series of types of physical damage, such as pulmonary edema and hydrothorax in pigs, leukoencephalomalacia in horses, etc. Human consumption of foods containing FB1 may cause esophageal cancer, liver, and kidney disease. Women who are exposed to high levels of fumonisins in their diet during early pregnancy have a high risk of bearing a child with a birth defect of the brain or spinal cord. FB1 also has the potential to cause heart failure in humans due to damages in myocardial contractility and massive blood influx, known as Idiopathic Congestive Cardiopathy (ICC). The aim of this study was to investigate the toxic effects of FB1 on animals and humans, as well as the toxic mechanism of FB1, and to provide a reference for subsequent research.

2. Contamination Caused by FB1

FB1 is mainly formed by the fungi encountered in the growing crop prior to harvesting, unlike ochratoxins and aflatoxins, and therefore development of the same fungi is often difficult to control or prevent. It mainly contaminates corn and corn products. In addition, FB1 also contaminates rice and other cereals such as oat, rye, barley, wheat, but at lower levels (Table 1). In 66 samples of maize and rice from Golestan province, Iran, FB1 was present in 50% of maize samples and 40.9% of rice samples with average levels of 223.64 μg/g and 21.59 μg/g, respectively. The European Community and the European Union have clear standards for the maximum limit of fumonisin in human foods and animal feeds (Table 2). Studies have shown that a hot and humid environment can lead to the increase of FB1 content. Fumonisins showed high stability in Maize at temperatures from 28.97 to 32.14 °C, humidity from 27.29 to 32.14%, and pH from 5.5. Thus, the hazard of FB1 to agricultural crops is reported more in countries in temperate tropical regions.

Since the feed is composed of corn and other cereals, contamination of animal feed by FB1 should be brought to attention (Table 1). In Bulgarian pig farms/chicken farms, the average FB1 content in feed samples in 2006 and 2007 was 5564.1 + 584.4 μg/kg and 3254.5 ± 480.6 μg/kg. In the feed samples from the South African pig farms, the mean FB1 levels detected in 2007 and 2008 were 5289 ± 1034 μg/kg and 5021 ± 844 μg/kg. These farms are plagued by kidney problems. In such a high concentration of FB1, this disease is likely to involve FB1. In a Spanish survey of pig feed samples, FB1 was also detected at a maximum of 3959 μg/kg. Pietsch conducted a risk assessment on FB1 in European fish feed. The sum of FB1 in the 12 feed components was 3576 μg/kg. Contamination with FB1 has been reported in feed ingredients and compound feeds in Korea, and its content is high, reaching a maximum of 14,900 ± 72.6 ng/g. In Chinese feed tests, 404 out of 420 feeds were contaminated, with the highest level being 6568 μg/kg. This seriously endangers the herd health and economic development. In the pet industry, the main components of some pet foods are corn and wheat, so FB1 can also contaminate pet foods. Although it is not abundant, it also causes chronic damage to pet bodies.

The effect of FB1 on humans depends mainly on the dietary habits of the area where they live. People in areas where corn and corn products are regularly consumed are exposed to FB1. Wheat products, although FB1 is also present but not at high levels, are less harmful to humans. In three remote Tanzanian villages, in which the child’s food during months 12–22 was predominantly corn based, 96% of urine samples tested positive for urinary fumonisin B1(UFB1). Kigwa had the highest UFB1 geometric mean 327.2 (217.1–493.0) pg/mL, followed by Nyabula at 211.7 (161.1–278.1) pg/mL, while Kikelelwa had the lowest at 82.8 (58.3–117.7) pg/mL. This was attributed to the different corn intakes in the three villages. Another experiment in Tanzania also demonstrated in three regions that the effect of FB1 on humans is related to corn intake, and its exposure to FB (FB1 + FB2) in 12-month-old infants was 4 μg/kg body weight/day. This value is higher than the provisional maximum tolerable daily intake (PMTDI) set by JECFA (2 µg/kg BW per day). Besides that, there are many countries whose exposure levels also exceed the PMTDI, such as Algerian, China, Mexico, etc. (Table 3). In the Netherlands, in people with celiac disease gluten induced enteropathy (intolerance to foods containing wheat gum) who were regularly exposed to corn, 37% of them consumed at least 105 ng FB1 and 97% of them at least 103 ng FB1 per day. It could also prove that the effects of FB1 in humans are mainly dependent on the amount of corn consumed. In Brazil, corn is cheap, so industrial beer with corn as the main ingredient is also contaminated by FB1. Various corn foods can also be contaminated by FB1, such as popcorn, cornmeal, corn snack, etc. (Table 1).

3.1. Effects on Sphingolipids

FB1 is a kind of diesters composed of different polyhydric alcohols and propionic acids. Its structure is composed of a long hydroxylated hydrocarbon chain, as well as surrounding tricarboxylic acids, methyl, and amino groups, and it resembles that of sphingolipids. Sphingolipids are components of the plasma membrane which are regulators of cell-to-cell interactions and cell-to-cell recognition. The hydrolytic skeleton of FB1 is very similar to sphingosine bases of sphingolipids (sphinganine (Sa) and sphingosine (So)). Sa is condensed by serine palmitoyl COA in vivo. Sa and So synthesize ceramide (Cer) under the action of ceramide synthase. FB1 can compete with Sa and So for ceramide synthase, inhibit ceramide synthase, leading to the production of dihydroceramide ceramide. In addition, the synthesis of sphingolipid complex (SLS) was decreased, the amounts of Sa and So increased, and the contents of sphinganine-1-phosphate and sphingosine-1-phosphate increased. It has been shown that the elevation of these substances is present before a significant rise in liver enzymes, so Sa, So, and Sa/So can be used as markers of FB1 exposure and thus detect FB1 exposure. According to the study, intravenous and oral administration of FB1 (exposure levels of 139 nmol and 3425 nmol b.w., respectively) resulted in a significant increase in the Sa/So ratio in the blood and cerebrospinal fluid of pigs, while treatment with fumonisin esterase resulted in a similar Sa/So as in the control group, suggesting that FB1 did interfere with sphingolipid metabolism. Generally, the Sa is elevated early in the process and the elevation is large: So is elevated later and the elevation is smaller. The ratios of Sa and So are time- and dose-dependent, and can vary depending on the amount of FB1 residing in the organ, which is related to the cell-specific function of sphingolipids in the same organ of different species.

3.2. Oxidative Stress

Some studies have found that FB1 intake also causes oxidative stress (OS). OS is a state of imbalance between reactive oxygen species (ROS) formation and antioxidant defense mechanisms in the body, and many diseases of old age are directly related to OS. When animals ingest FB1, intracellular markers of OS, such as ROS, are increased and generate a highly-oxidized environment with an increased content of the intracellular antioxidant. When ROS concentration exceeds antioxidant capacity, OS occurs in cells.

Oxidative stress of FB1 induced cytotoxicity and decreased cellular activity. In the study, it was found that FB1 (100 mM for 0–144 h) induced a dose-dependent increase of ROS production in C6 glioblastoma and GT1-7 hypothalamic cells, but had no significant effect on SH-SY5Y cells. In parallel, these three cell lines exhibited decreased glutathione (GSH) levels, increased malondialdehyde (MDA) production, lipid peroxidation and necrotic cell death. Pig Iliac Endothelium Cells (PIECs) were treated with 50 μg/mL FB1, and the content of MDA increased and GSH decreased after 48 h. At the same time, the activities of antioxidant enzymes such as Superoxide dismutase (SOD), Glutathione peroxidase (GSH-Px), Catalase (CAT), and Thioredoxin reductase (TrxR) decreased significantly, and the elevation of MDA leads to cell membrane lipid peroxidation, resulting in cell membrane damage and reduced cell activity. The barrier functional integrity of PIECs cells was also measured, and it was found that FB1 may affect the expression of tight junction proteins in porcine vascular endothelial cells and alter the intercellular junctions.

The oxidative stress caused by FB1 induces DNA damage, and DNA damage induces cell carcinogenesis. It has been shown that FB1 increases the level of 8-hydroxy-2′-deoxyguanosine (8-OH-DG) in rat C6 glioma cells and p53-null mouse embryo fibroblasts. 8-OH-DG is a biomarker of oxidative DNA damage, which induces DNA hypomethylation and thus affects cellular stability. This result is identical to the study by Demirel et al. and Arumugam et al.. In the experiments on rat liver epithelial cell line (Clone 9) and rat kidney proximal tubular epithelial cell line (NRK-52E), FB1 leads to methylation of tumor-related genes (p16, VHL, E-cadherin, and c-myc). Arumugam et al. showed that, in HepG2 cells, FB1 suppressed the activity of checkpoint kinase 1 (CHK1) to generate DNA damage by regulating phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinases (PI3K) and protein kinase B (Akt). This result is similar to that of Yu et al.. They found that FB1 was through the PI3K/Akt signaling pathway, which regulated cell survival. They also found that FB1 could increase the expression of HDACs in HEECs. Among epigenetic proteins, histone deacetylases (HDACs) have emerged as potential therapeutic targets for many diseases including cancer. Aberrant epigenetic changes may lead to chromatin instability and reduced levels of histone acetylation, which may be responsible for FB1 carcinogenesis. FB1 also causes methylation of RNA, which is due to elevation of N6 methyladenosine (m6A). Meanwhile, hypermethylation of the kelch-like ECH associated protein 1 (Keap1) promoter and hypomethylation of the related factor 2 (Nrf2) promoter, a decrease in mir-27b, and an increase in m6a-keap1 and m6a-nrf2 also lead to the activation of the keap1-nrf2 signaling pathway.

Oxidative stress of FB1 induces apoptosis and cellular autophagy. ROS production in cells downregulates MAPKs-specific phosphatases, thereby affecting the activation of mitogen-activated protein kinase (MAPKs). FB1 at 0.5 mg/kg was administered to the liver and kidney of rats, and the signal of c-Jun N-terminal kinase (JNK) was detected in the liver after 7 days, and the signal of all three MAPKs (extracellular regulated protein kinases (ERK), JNK, and P38) was increased in the kidney. It was also reported that FB1 could significantly increase the phosphorylation of JNK protein, but had no obvious effect on the phosphorylation of ERK and p38. In a mouse colon model, FB1-mediated oxidative stress and Ca++ release from the endoplasmic reticulum induced JNK phosphorylation, activated P53 signaling, led to the expression of apoptotic signaling molecules Programmed Cell Death (PUMA) and Caspase-3, and induced apoptosis. BCL2-Associated X (Bax) is a pro-apoptotic gene, which is activated by P53 in vivo and enters the mitochondria to help produce cytochrome C, which further produces Caspase-9 and activates Caspase-3 to induce apoptosis. Oxidative stress-mediated activation of JNK simultaneously leads to phosphorylation of B-cell lymphoma-2 (Bcl-2) and release of Beclin1, which indirectly stimulates the expression of LC3- II or LC3- I and induces autophagy.

3.3. Endoplasmic Reticulum Stress

When cells are strongly stimulated by various factors, the ability to correctly fold and post-translationally modify the secreted transmembrane proteins in the endoplasmic reticulum is hindered, resulting in a large accumulation of misfolded proteins in the organelles and causing endoplasmic reticulum stress.

FB1 induces ER stress in mouse liver cells and HepG2 cells. After treating mouse hepatocytes and HepG2 cells with FB1, we found that the expression of protein kinase R-like ER kinase (PERK), Inositol-requiring enzyme-1αIRE1-α, and autophagy marker (LC3I/II), which are related to autophagy in ER stress, were significantly increased. The phosphorylation expression of AMP-dependent protein kinase (AMPK) is elevated, and the phosphorylation expression of mammalian target of rapamycin (mTOR) is decreased, thereby triggering cell autophagy. This notion was also demonstrated by Hou et al., who found that FB1 was through mTORC1 to mediate autophagy induced nephrotoxicity. The expression level of glucose regulatory protein 78 (Bip), activated transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) was also significantly elevated in HepG2 cells. It has been suggested that this is due to the activation of the PERK-CHOP signaling pathway by FB1, which induces apoptosis. The toxic effect of endoplasmic reticulum on AML12 mouse liver cells was reported to be through the IRE1α pathway, but not the PERK pathway, but the mechanism of the IRE1α signaling pathway was not described and may require further study. Meanwhile, two experiments in GES-1 and AML12 mouse liver cells suggest that the endoplasmic reticulum stress pathways caused by different organs may be different, and the specificity to organs needs to be further investigated. This report also showed that inhibition of endoplasmic reticulum stress significantly reduced the hepatotoxicity of FB1, which may be a good way to reduce the toxicity of FB1 to the liver.

3.4. TNF Signaling Pathway

The toxicity of FB1 is related to TNF-α. In experiments with Gastric epithelial (AGS) and human colon adenocarcinoma cell line (SW742), FB1 was found to induce a dose-dependent increase in the expression of tumor necrosis factor (TNFα) and IL-1β in these two cell types, thus suggesting that FB1 can promote cytokine production by gastrointestinal cells, which may underlie the subsequent onset of inflammation. Recent articles have shown that FB1 can upregulate the expression of TNF signaling pathway-related mRNA in porcine kidney cells (PK-15) cells and that tumor necrosis factor α (TNFα) is a key substance causing toxicity. It was also demonstrated that NF-κB is an important target in the TNF signaling pathway. The involvement of this signaling pathway was also found in porcine jejunum and liver, where a significantly elevated expression of NF-κB and Interleukin-8 (IL-8) could be detected, leading to apoptosis.

The mechanism diagram of FB1 is shown in Figure 2.

4.1. Immunotoxicity

FB1 has some immunotoxicity. Intragastric administration of FB1 (80 mg/kg BW) to mice for two weeks reduced spleen weight and also caused 12.9% thymocyte apoptosis. This finding is akin to that of avian species, where FB1 significantly reduced splenocyte activity at a dose of 50 μg/mL and the results were consistent at 24, 48, and 72 h.

FB1 acted on cytokine expression, and one study showed that gavage of BALB/c mice with FB1 (100 mg/kg) for two weeks resulted in an increased expression of interleukin-10 (IL-10) and interleukin-4 (IL-4) mRNA in the spleen and a decreased expression of interferon-γ (IFN-γ) and tumor necrosis factor (TNFα) mRNA. Interestingly, Taranu et al. (2005) found that the exposure of weaned piglets to 1.5 mg/kg could decrease IL-4mRNA expression and increase IFN-γ synthesis, which may be related to species and FB1 dose. The FB1 uptake was found to interfere with the specific immune response of animals during vaccination. This is because FB1 decreases the level of specific antibodies in the serum of piglets, thus causing a decrease in the specific immune response to the vaccine antigen. This is similar to the findings of Stoev et al.. He found that when the content of FB1 in the feed was 10 mg/kg, it could significantly reduce the antibody titer and interfere with the humoral immune response during vaccination. In experiments by Li et al. (2017), it was found that FB1 reduced the immune responsiveness of bone marrow-derived dendritic cells (BMDCs), and the number of dendrites in BMDCs was significantly decreased under treatment using 1000 ng/mL FB1 compared to positive controls, and LPS-induced expression of CD80, CD86, and MHCII changed from up-regulation to down-regulation in response to FB1. In humans, FB1 inhibits the expression of HLA class I antigen and low molecular weight proteasome 2 (LMP2) and transporter associated with antigen presentation (TAP1) and increases the chance of survival of abnormal cells. This is similar to the results of aflatoxin G1. This result may induce cancer, but its relationship with cancer needs further experimental study. However, FB1 had no effect on HLA-C expression at the mRNA level.

Immune cells were important targets for the toxic effects of FB1. After 72 h of exposure at a concentration of 101.15 μg/mL, the cellular activity of porcine lymphocytes decreased to 50% of its original level. Lymphocyte survival in humans decreased by 3.5% and 11.3% after 24 h of exposure to concentrations of 5 and 20 μg/mL, respectively. Macrophage chemotaxis and phagocytosis were reduced when FB1 (15 mg/kg) was administered to broiler chickens. A decrease in macrophage capacity led to metabolic and immune system disorders in birds, intensifying the severity of chlamydia. FB1 can also suppress the non-specific immune system of pigs, reducing macrophage capacity and exacerbating pathogen infection. A study of the effects of FB1 on Mycoplasma pneumoniae infection in swine found that feeding FB1 at 20 mg/kg could aggravate the progression of infection. FB1 also significantly increases colonization of the small and large intestine by extra-intestinal pathogenic E. coli strains. Some studies have shown that administration of different doses of FB1 (11.8 mg/kg, 0.5 mg/kg, and 20 mg/kg) can complicate the infection process of Bacillus subtilis A, causing interstitial bronchial pneumonia. Recent studies have shown that non cytotoxic doses of FB1 can aggravate OTA induced cytotoxicity and apoptosis. This process has JNK/MAPK pathway involvement. There are currently many human and animal foods that still contain high doses of FB1.Therefore, the synergistic mechanism of FB1 against various pathogenic flora and microorganisms should be further investigated, so as to evaluate the extent to which FB1 is involved in the development of infectious diseases in humans and animals.

4.2. Organ Toxicity

A series of studies have shown that FB1 has certain toxic effects in organs such as liver, lung, kidney, heart, and intestine in different animals (Table 4). After continuous gavage delivering FB1 (100 mg/each) for 5 to 11 days, samples of various organs were collected and analyzed for FB1 residues: particularly high levels were detected in kidney (mean 824 mg/g), liver (231 mg/g), lung (170 µg/g), and spleen (854 µg/g). A single subcutaneous injection of FB1 (25 mg/kg) in mice resulted in a sustained increase in Sa content in the kidney and in concentrations much greater than those in the liver and intestine. It has also been shown that FB1 intraperitoneal injection in C57BL6 mice (8 mg/kg BW) decreased oxidative defense in the liver and kidneys, while having no effect on the lungs. In poultry, the highest concentration of FB1 was found in the liver, lower in the kidney than in the liver, and the muscles were the least contaminated. This suggests that FB1 acts to different degrees in different organs of different animals. It has been suggested that this difference may be due to the ratio of ceramide CerS (CerS4, CerS2, and CerS1) protein expression in each tissue and the affinity of FB1 for these proteins. Among them, the liver and kidney are important targets for the toxic effects of FB1 on the organism.

4.2.1. Toxic Effects of FB1 on the Liver

The liver is one of the main target organs of FB1 in the body, and the main symptoms are cirrhosis, failure, and in severe cases, liver necrosis and liver cancer. Treatment of rats by gavage (FB1, 50 mg/kg, 6 doses over 11 days) induced hepatic edema, intrahepatic monocyte necrosis, and also caused early phenomena of lipid accumulation and liver fibrosis. In a pig trial, after feeding FB1 (1.5 mg/kg BW) for nine consecutive days, liver weight did not increase, but plasma total cholesterol (TC) and aspartate transferase (AST) were significantly elevated, indicating liver damage. After feeding feeds with FB1 (7.5 mg/kg and 10 mg/kg for 196 days) to rabbits, hepatic necrosis developed and a large number of macrophages and lymphocytes were found in the periphery. For this phenomenon, Neelesh et al. performed experiments with mice and concluded that the production of pro-inflammatory cytokines after T-cell activation is an important mechanism by which FB1 causes hepatotoxicity in mice and that this mechanism does not affect the accumulation of sphingoid bases.

FB1 may induce liver cancer. FB1 induced liver tumors in female B6C3F1 mice. In rats treated by gavage it was shown that the effective dosage level (EDL) for cancer over 21 days was 14.2 < EDL < 30.8 mg Fb1/100 g bw, and the EDL value for carcinogenicity within 14 days was 23.3 < EDL < 33.3 mg Fb1/100g bw. It has been shown that FB1 induces cancer by regulating the levels of fatty acids, cholesterol, and sphingolipids, leading to the disruption of membrane microdomains and lipid rafts. It has also been shown that FB1 causes methylation of oncogene (c-myc) in the rat liver epithelial cell line (Clone 9), suggesting that methylation of DNA is also a cause of cancer.

4.2.2. Toxic Effects of FB1 on the Kidney

The kidneys are also highly sensitive to FB1. It has been shown that the concentration of FB1 that caused nephrotoxicity in Sprague-Dawley rats in a 4-week feeding study was much lower than that required to cause hepatotoxicity. This was also demonstrated by Szabó et al. with a higher sensitivity of rat kidneys to FB1 at low doses and relatively short-term FB1 exposure. Bondy et al. injected rats with purified FB1 (0.75 mg/kg) for six consecutive days and observed a small amount of renal damage and renal epithelial cell shedding. This result is similar to that of Szabó et al. where the same shedding of renal epithelial cells and an increase in urine volume and potassium excretion were found after the administration of FB1 (≥50 mg/kg) to rats. Renal epithelial cell shedding may lead to cell loss and impaired replacement, which may induce cancer. Some characteristic changes can also be observed in the kidneys of pigs. Such as mild to moderate vacuolar or granular degeneration of proximal tubule epithelial cells, hyperaemia of vessels and peritubular capillaries, mild activation of capillary endothelial cells, mild mononuclear proliferation in interstitium, perivascular or pericapillary edema, and enlarged lymphatic vascular spaces. Protein debris is seen within the lumen of some renal tubules.

FB1 similarly induced renal tumors. The induction rate of renal tubular carcinoma was significantly increased in male F344 rats after feeding diets containing FB1 (50 mg/kg and 100 mg/km). The mechanism of FB1-induced renal tumors is similar to that in the liver. In rat kidney proximal tubular epithelial cell line (NRK-52E), promoter methylation of the tumor suppressor gene (VLH) was found, and FB1-induced DNA methylation was suggested to be an important cause of cancer induction. It has also been found in NKR-52e that FB1 perturbs epigenetics by altering global histone modifications, which in turn induces cancer. Further studies can provide more insight into the mechanism of FB1 toxicity.

4.2.3. Toxic Effects of FB1 on the Intestinal Tract

FB1 causes disruption of the intestinal epithelial barrier, epithelial cell detachment, inflammatory cell infiltration, atrophy and necrosis, and different intestinal targets in different animals. In tests in pigs, oral administration of FB1-rich extracts was found to significantly increase the concentration of stress proteins in the colon, a response that was stronger than in the stomach or in the small intestine. In contrast, in studies in rats, the damage was more severe in the duodenum and cecum, and the cause of this intestine-specific damage is not known. FB1 enhances the permeability of porcine intestinal epithelial cells (IPEC-J2), and long-term exposure to FB1 inhibits the proliferation of IPEC-J2, leading to an impaired cell barrier, a toxic effect that may be related to the ERK1/2 phosphorylation pathway. This study also showed that the toxic effects of FB1 on the intestine were associated with elevated Ca2+ ions and alterations in cytochrome (CYP)-related enzymes.

4.2.4. Toxic Effects of FB1 on the Heart and Lungs

The lung effects of FB1 were mainly caused by pulmonary edema in animals, with FB1 having the most serious effect on the lungs of pigs. The main pathological manifestations were the accumulation of serous or serofibrinous exdate in interlobular tissue or alveolar lumina and the thickening of interalveolar septa due to epithelial hyperplasia and/or accumulation of fibrin. This is due to the cardiovascular effects induced by FB1 that block sphingosine mediated l-type Ca (2+) channels, which leads to left heart failure and triggers pulmonary edema. FB1 decreases heart rate, myocardial contractility, and arterial blood pressure. Alterations in the sphingolipid biosynthetic pathway affect the cardiovascular system of pigs. Elevated concentrations of sphinganine (Sa) and sphingosine (So) cause systemic hypotension, and elevated concentrations of sphingosine-1-phosphate cause pulmonary hypertension.

4.2.5. Toxic Effects of FB1 on the Brain

FB1 can also cause damage to the brain, the most obvious example of which is leukoencephalomalacia in horses, which leads to neurotoxic symptoms and, in some cases, abnormal optic nerve function. The horse was given FB1 (0.2 mg/kg) daily, and over a period of four to 10 days, ataxia of the hindlimbs and trunk, depression, hypertension, and intermittent dementia developed. It has been suggested that this is because the intracranial pressure in horses is affected by eating with the head down and that FUMs block normal vascular regulatory mechanisms leading to cerebral edema. Rats receiving FB1 (6.2 mg/kg) had a significantly reduced nerve conduction velocity after two weeks. After pigs were fed a mold diet containing FB1 (10 mg/kg), the cerebral cortex was vacuolated and some neuronal and glial cytolysis under the meninges could be seen. The meninges showed signs of edema and congestion. The necropsy of beef cattle having a sudden onset of blindness after grazing on standing corn contaminated with Fumonisin-producing Fusarium species revealed optic nerve degeneration and acute myelin edema. Kovacić et al. added FB1 (100 mg/kg) to carp feed and found that FB1 can penetrate the blood-brain barrier of carp, causing degeneration and necrosis of nerve cells and brain edema. FB1 has also been found to cause human embryonic neural tube defects (NTD) that inhibit neurodevelopment. This phenomenon has also been observed in mouse models, where pregnant LM/BC mice injected with FB1 (20 mg/kg b.w.) at gestation day (GD) 7.5 and GD 8.5 had a 79% probability of developing NTD, and NTD was found to be preventable with timely folic acid supplementation. However, Voss et al. experiment showed that folic acid deficiency did not aggravate the NTD (A29.75) induction in LM/BC mice. At present, there is no clear experiment to show the mechanism of NTD induced by FB1, which needs further study.

4.2.6. Toxic Effects of FB1 on Human Organs

FB1 may induce human esophageal cancer, which has been reported in Kenya, Huai’an, and other places. FB1 was found to promote the value-added of normal human esophageal epithelial cells (HEECs) while decreasing the ratio of G0/G1 cells. This alteration may be due to FB1 upregulating the expression of cell cycle protein D1, which inhibits the expression of P21 and P27. Meanwhile, the expression of these three substances has been shown to be associated with esophageal cancer. It has also been suggested that FB1 is a promoter or initiator of certain carcinogens, acting synergistically. Recent studies have shown that FB1 functions to promote cell migration and proliferation. In HEECs, FB1 can suppress the expression of tumor suppressor genes (phosphatase and tensin homologue (PTEN) and adenomatous polyposis coli (APC)), activate the PI3K/Akt signaling pathway, and regulate cell survival. Ultimately, this leads to cell cycle dysregulation that promotes cell proliferation. HDAC have been implicated in FB1 induced carcinogenesis in HEECs.

Similar to pigs, FB1 also reduces cardiac contractility in humans, triggering idiopathic congestive cardiopathy (ICC). This is caused by massive blood flow into the heart and weakness of the heart. Women in early pregnancy are at risk of giving birth to babies with NTDs on a long-term basis consuming foods containing high concentrations of FB1. The probability of this risk is proportional to the dose, and fetal death may occur in severe cases.

The organ toxicity hazard of FB1 in humans is mainly manifested from in vitro models (Table 5). FB1 has some toxic effects on human intestinal cell lines, but the toxicity is low. It has been found that at a concentration of 400 ppb, it causes peroxidation of intestinal cell lines, and elevated concentrations cause changes in mucosal concentrations as well as inflammation, but normal food contains 31.5–74.2 ppb of FB1, so it hardly causes intestinal problems in the normal daily diet. In experiments using a human gastric epithelial cell line (GES-1) as an in vitro model, FB1 was found to significantly reduce cell viability, increase membrane leakage, cell death, and induce endoplasmic reticulum stress, resulting in gastrointestinal injury. Recent studies have shown that the endoplasmic reticulum stress-associated PERK-CHOP signaling pathway plays a key role in FB1 damage to GES-1. This may be a new mechanism that needs further study.

FB1 also inhibits the value addition and prolonged cell cycle of the human normal hepatocyte line HL-7702, which may be related to FB1-induced changes in the expression levels of cyclins E and P21. In a human hepatocellular carcinoma cell line (HepG2), the expression levels of miR-27b and CYP1B1 protein were significantly negatively correlated, which may be a mode of liver tumor transformation However, after studying FB1 levels in 271 liver cancer patients and 280 normal subjects, some scholars concluded that there is no direct association between FB1 intake and liver cancer. Further studies are needed to prove the relationship between FB1 and liver cancer.

4.3. Reproductive Toxicity

The effects of FB1 on the reproductive system mainly include reproductive failure and fetal hypoplasia in some animals. FB1 reduces gonadotropin levels, inhibits granulocyte gain, and impairs normal follicle growth and oocyte survival. Upon treatment of porcine cumulus oocyte complexes (COCs) with FB1 (30–40 mM), the expulsion of the first polar body was inhibited and oocyte meiotic progression was disrupted. Oocytes were arrested at the germinal vesicle breakdown (GVBD) stage. This may be because FB1 induces oxidative stress in porcine oocytes, which in turn triggers oocyte apoptosis. FB1 (15 or 18 mg/kg) was administered to Syrian mice and the number of litters was significantly decreased. Mouse embryos showed stunted development after 26 h of exposure to FB1 (≥1.44 mg/kg) and after exposure to FB1 (36 mg/kg) for 2 h. FB1 also reduced body mass, litter size, and feeding capacity in pregnant rats, resulting in craniosynostosis and sternal deformity in the fetus. When the male rabbits were exposed to FB1 with a concentration of up to 7.5 mg/kg, the sperm reserves of testis and epididymis were reduced, sperm production was inhibited, and a potential reproductive obstacle ensued, leading to embryo death in the later stage of embryo development. When exposed to 10 mg/kg FB1, mild or moderate testicular lesions and Sertoli cell degeneration were found in rabbits.

5. Perspectives

Based on the above literature, it is suggested that the toxic effects of FB1 can have a great impact on animal husbandry and also cause a certain threat to human health. In this paper, we examined the contamination of FB1 in food and feed and the mechanism of FB1 toxicity on animal and human beings. At present, the synergistic mechanism of FB1 with mycotoxins as well as other microorganisms needs further investigation. The toxic effects of FB1 on epigenetics are also a major trend in research. Further research on the toxicity mechanism of FB1 in animal and human organism can reduce the toxicity hazard and reduce the economic loss in the farming industry.

References 156

  1. 1.

    Dutton M.F., Kinsey A. Occurrence of mycotoxins in cereals and animal feedstuffs in Natal, South Africa 1994. Mycopathologia. 1995;131:31-36.

    Not in our library10.1007/bf01103901

  2. 2.

    Shephard G.S., Thiel P.G., Stockenström S., Sydenham E.W. Worldwide Survey of Fumonisin Contamination of Corn and Corn-Based Products. J. AOAC Int. 1996;79:671-687.

    Not in our library10.1093/jaoac/79.3.671

  3. 3.

    Stoev S., Dutton M., Njobeh P., Mosonik J., Steenkamp P. Mycotoxic nephropathy in Bulgarian pigs and chickens: Complex aetiology and similarity to Balkan Endemic Nephropathy. Food Addit. Contam. Part A. 2010;27:72-88.

    Not in our library10.1080/02652030903207227

  4. 4.

    Stoev S.D., Denev S., Dutton M.F., Njobeh P.B., Mosonik J.S., Steenkamp P.A., Petkov I. Complex etiology and pathology of mycotoxic nephropathy in South African pigs. Mycotoxin Res. 2009;26:31-46.

    Not in our library10.1007/s12550-009-0038-7

  5. 5.

    Gelderblom W.C., Jaskiewicz K., Marasas W.F., Thiel P.G., Horak R.M., Vleggaar R., Kriek N.P. Fumonisins-novel mycotoxins with cancer-promoting activity produced by Fusarium moniliforme. Appl. Environ. Microbiol. 1988;54:1806-1811.

    Not in our library10.1128/aem.54.7.1806-1811.1988

  6. 6.

    Bezuidenhout S.C., Gelderblom W.C.A., Gorst-Allman C.P., Horak R.M., Marasas W.F.O., Spiteller G., Vleggaar R. Structure elucidation of the fumonisins, mycotoxins from Fusarium moniliforme. J. Chem. Soc. Chem. Commun. 1988;11:743-745.

    Not in our library10.1039/c39880000743

  7. 7.

    FAO. Evaluation of Certain Contaminants in Food. 2017;1-166.

    Not in our library

  8. 8.

    Ahangarkani F., Rouhi S., Azizi I.G. A review on incidence and toxicity of fumonisins. Toxin Rev. 2014;33:95-100.

    Not in our library10.3109/15569543.2013.871563

  9. 9.

    Waes J.G.-V., Starr L., Maddox J., Aleman F., Voss K.A., Wilberding J., Riley R.T. Maternal fumonisin exposure and risk for neural tube defects: Mechanisms in an In Vivo mouse model. Birth Defects Res. Part A Clin. Mol. Teratol. 2005;73:487-497.

    Not in our library10.1002/bdra.20148

  10. 10.
    Exposure to Fumonisins and the Occurrence of Neural Tube Defects along the Texas–Mexico Border · 2005
    No notice
  11. 11.

    Stoev S.D. Foodborne mycotoxicoses, risk assessment and underestimated hazard of masked mycotoxins and joint mycotoxin effects or interaction. Environ. Toxicol. Pharmacol. 2015;39:794-809.

    Not in our library10.1016/j.etap.2015.01.022

  12. 12.

    Stoev S.D. Food Safety and Increasing Hazard of Mycotoxin Occurrence in Foods and Feeds. Crit. Rev. Food Sci. Nutr. 2013;53:887-901.

    Not in our library10.1080/10408398.2011.571800

  13. 13.

    Hanvi D.M., Lawson-Evi P., De Boevre M., Goto C.E., De Saeger S., Eklu-Gadegbeku K. Natural occurrence of mycotoxins in maize and sorghum in Togo. Mycotoxin Res. 2019;35:321-327.

    Not in our library10.1007/s12550-019-00351-1

  14. 14.

    Ponce-García N., Serna-Saldivar S.O., García-Lara S. Fumonisins and their analogues in contaminated corn and its processed foods—A review. Food Addit. Contam. Part A. 2018;35:2183-2203.

    Not in our library10.1080/19440049.2018.1502476

  15. 15.

    Alizadeh A.M., Roshandel G., Roudbarmohammadi S., Roudbary M., Sohanaki H., Ghiasian S.A., Taherkhani A., Semnani S., Aghasi M. Fumonisin B1 Contamination of Cereals and Risk of Esophageal Cancer in a High Risk Area in Northeastern Iran. Asian Pac. J. Cancer Prev. 2012;13:2625-2628.

    Not in our library10.7314/apjcp.2012.13.6.2625

  16. 16.

    Cendoya E., Monge M.D.P., Chiacchiera S.M., Farnochi M.C., Ramirez M.L. Influence of water activity and temperature on growth and fumonisin production by Fusarium proliferatum strains on irradiated wheat grains. Int. J. Food Microbiol. 2018;266:158-166.

    Not in our library10.1016/j.ijfoodmicro.2017.12.001

  17. 17.

    Rheeder J., van der Westhuizen L., Imrie G., Shephard G.S. Fusariumspecies and fumonisins in subsistence maize in the former Transkei region, South Africa: A multi-year study in rural villages. Food Addit. Contam. Part B. 2016;9:176-184.

    Not in our library10.1080/19393210.2016.1154612

  18. 18.

    Liverpool-Tasie L.S.O., Turna N.S., Ademola O., Obadina A., Wu F. The occurrence and co-occurrence of aflatoxin and fumonisin along the maize value chain in southwest Nigeria. Food Chem. Toxicol. 2019;129:458-465.

    Not in our library10.1016/j.fct.2019.05.008

  19. 19.

    van Rensburg B.J., McLaren N., Flett B. Grain colonization by fumonisin-producing Fusarium spp. and fumonisin synthesis in South African commercial maize in relation to prevailing weather conditions. Crop. Prot. 2017;102:129-136.

    Not in our library10.1016/j.cropro.2017.08.019

  20. 20.

    Bryła M., Waśkiewicz A., Szymczyk K., Jędrzejczak R. Effects of pH and Temperature on the Stability of Fumonisins in Maize Products. Toxins. 2017;9:88.

    Not in our library10.3390/toxins9030088

  21. 21.
    Occurrence of Mycotoxins in Swine Feeding from Spain · 2019
    Not checked
  22. 22.

    Pietsch C. Risk assessment for mycotoxin contamination in fish feeds in Europe. Mycotoxin Res. 2020;36:41-62.

    Not in our library10.1007/s12550-019-00368-6

  23. 23.

    Seo D.-G., Phat C., Kim D.-H., Lee C. Occurrence of Fusarium Mycotoxin Fumonisin B1 and B2 in Animal Feeds in Korea. Mycotoxin Res. 2013;29:159-167.

    Not in our library10.1007/s12550-013-0172-0

  24. 24.

    Wang Y., Liu S., Zheng H., He C., Zhang H. T-2 toxin, zearalenone and fumonisin B1in feedstuffs from China. Food Addit. Contam. Part B. 2013;6:116-122.

    Not in our library10.1080/19393210.2013.764506

  25. 25.

    Witaszak N., Waśkiewicz A., Bocianowski J., Stępień Ł. Contamination of Pet Food with Mycobiota and Fusarium Mycotoxins—Focus on Dogs and Cats. Toxins. 2020;12:130.

    Not in our library10.3390/toxins12020130

  26. 26.

    Shirima C.P., Kimanya M.E., Kinabo J.L., Routledge M., Srey C., Wild C.P., Gong Y.Y. Dietary exposure to aflatoxin and fumonisin among Tanzanian children as determined using biomarkers of exposure. Mol. Nutr. Food Res. 2013;57:1874-1881.

    Not in our library10.1002/mnfr.201300116

  27. 27.

    Kamala A., Kimanya M., Lachat C., Jacxsens L., Haesaert G., Kolsteren P., Ortiz J., Tiisekwa B., De Meulenaer B. Risk of Exposure to Multiple Mycotoxins from Maize-Based Complementary Foods in Tanzania. J. Agric. Food Chem. 2017;65:7106-7114.

    Not in our library10.1021/acs.jafc.6b03429

  28. 28.

    De Nijs M., Van Egmond H.P., Nauta M., Rombouts F.M., Notermans S.H.W. Assessment of Human Exposure to Fumonisin B1. J. Food Prot. 1998;61:879-884.

    Not in our library10.4315/0362-028x-61.7.879

  29. 29.
    Mycotoxin profiling of 1000 beer samples with a special focus on craft beer. · 2017
    Not checked
  30. 30.

    Phoku J., Dutton M., Njobeh P., Mwanza M., Egbuta M., Chilaka C. Fusarium infection of maize and maize-based products and exposure of a rural population to fumonisin B1in Limpopo Province, South Africa. Food Addit. Contam. Part A. 2012;29:1743-1751.

    Not in our library10.1080/19440049.2012.708671

  31. 31.

    Mahdjoubi C.K., Arroyo-Manzanares N., Hamini-Kadar N., García-Campaña A.M., Mebrouk K., Gámiz-Gracia L. Multi-Mycotoxin Occurrence and Exposure Assessment Approach in Foodstuffs from Algeria. Toxins. 2020;12:194.

    Not in our library10.3390/toxins12030194

  32. 32.

    Ortiz J., Van Camp J., Mestdagh F., Donoso S., De Meulenaer B. Mycotoxin co-occurrence in rice, oat flakes and wheat noodles used as staple foods in Ecuador. Food Addit. Contam. Part A. 2013;30:2165-2176.

    Not in our library10.1080/19440049.2013.853228

  33. 33.

    Chehri K., Jahromi S.T., Reddy K.R.N., Abbasi S., Salleh B. Occurrence of Fusarium spp. and Fumonisins in Stored Wheat Grains Marketed in Iran. Toxins. 2010;2:2816-2823.

    Not in our library10.3390/toxins2122816

  34. 34.

    Peluque E., Neres N., Michelin E., Reis T., Rosim R., Oliveira C., Sousa R., Corrêa B., Fernandes A. Fumonisin B1in cereal mixtures marketed in Brazil. Food Addit. Contam. Part B. 2014;7:46-48.

    Not in our library10.1080/19393210.2013.841294

  35. 35.

    Fazekas B., Bajmócy E., Glávits R., Fenyvesi A., Tanyi J. Fumonisin B1 Contamination of Maize and Experimental Acute Fumonisin Toxicosis in Pigs. J. Vet. Med. Ser. B. 1998;45:171-181.

    Not in our library10.1111/j.1439-0450.1998.tb00780.x

  36. 36.

    Castellá G., Bragulat M.R., Cabañes F.J. Surveillance of fumonisins in maize-based feeds and cereals from Spain. J. Agric. Food Chem. 1999;47:4707-4710.

    Not in our library10.1021/jf981236d

  37. 37.

    Tarazona A., Gómez J., Mateo F., Jiménez M., Mateo E. Potential Health Risk Associated with Mycotoxins in Oat Grains Consumed in Spain. Toxins. 2021;13:421.

    Not in our library10.3390/toxins13060421

  38. 38.

    Liu Y., Jiang Y., Li R., Pang M., Liu Y., Dong J. Natural occurrence of fumonisins B1 and B2 in maize from eight provinces of China in 2014. Food Addit. Contam. Part B. 2017;10:113-117.

    Not in our library10.1080/19393210.2017.1280541

  39. 39.

    Sun G., Wang S., Hu X., Su J., Zhang Y., Xie Y., Zhang H., Tang L., Wang J.-S. Co-contamination of aflatoxin B1and fumonisin B1in food and human dietary exposure in three areas of China. Food Addit. Contam. Part A. 2011;28:461-470.

    Not in our library10.1080/19440049.2010.544678

  40. 40.

    Mac M., Soares L.M.V. Fumonisins B1and B2in Brazilian corn-based food products. Food Addit. Contam. 2000;17:875-879.

    Not in our library10.1080/026520300420466

  41. 41.

    Piacentini K.C., Rocha L., Fontes L.C., Carnielli L., Reis T., Corrêa B. Mycotoxin analysis of industrial beers from Brazil: The influence of fumonisin B1 and deoxynivalenol in beer quality. Food Chem. 2017;218:64-69.

    Not in our library10.1016/j.foodchem.2016.09.062

  42. 42.

    Bordin K., Rosim R., Neeff D., Rottinghaus G., Oliveira C. Assessment of dietary intake of fumonisin B1 in São Paulo, Brazil. Food Chem. 2014;155:174-178.

    Not in our library10.1016/j.foodchem.2014.01.057

  43. 43.

    Roscoe V., Lombaert G.A., Huzel V., Neumann G., Melietio J., Kitchen D., Kotello S., Krakalovich T., Trelka R., Scott P.M. Mycotoxins in breakfast cereals from the Canadian retail market: A 3-year survey. Food Addit. Contam. Part A. 2008;25:347-355.

    Not in our library10.1080/02652030701551826

  44. 44.

    Lino C., Silva L., Pena A., Fernández M., Mañes J. Occurrence of fumonisins B1 and B2 in broa, typical Portuguese maize bread. Int. J. Food Microbiol. 2007;118:79-82.

    Not in our library10.1016/j.ijfoodmicro.2007.04.014

  45. 45.

    Martins H.M., Almeida I., Marques M.C., Guerra M. Fumonisins and deoxynivalenol in corn-based food products in Portugal. Food Chem. Toxicol. 2008;46:2585-2587.

    Not in our library10.1016/j.fct.2008.03.030

  46. 46.

    Aoyama K., Nakajima M., Tabata S., Ishikuro E., Tanaka T., Norizuki H., Itoh Y., Fujita K., Kai S., Tsutsumi T., et al. Four-Year Surveillance for Ochratoxin A and Fumonisins in Retail Foods in Japan. J. Food Prot. 2010;73:344-352.

    Not in our library10.4315/0362-028x-73.2.344

  47. 47.

    Seo E., Yoon Y., Kim K., Shim W.-B., Kuzmina N., Oh K.-S., Lee J.-O., Kim D.-S., Suh J., Lee S.-H., et al. Fumonisins B1 and B2 in Agricultural Products Consumed in South Korea: An Exposure Assessment. J. Food Prot. 2009;72:436-440.

    Not in our library10.4315/0362-028x-72.2.436

  48. 48.

    Jiang D., Li F., Zheng F., Zhou J., Li L., Shen F., Chen J., Li W. Occurrence and dietary exposure assessment of multiple mycotoxins in corn-based food products from Shandong, China. Food Addit. Contam. Part B. 2019;12:10-17.

    Not in our library10.1080/19393210.2018.1503341

  49. 49.

    Yazdanpanah H., Shephard G.S., Marasas W.F.O., van der Westhuizen L., Rahimian H., Safavi S.N., Eskandari P., Ghiasian S.A. Human Dietary Exposure to Fumonisin B1 from Iranian Maize Harvested During 1998–2000. Mycopathologia. 2006;161:395-401.

    Not in our library10.1007/s11046-006-0017-x

  50. 50.

    Gilbert-Sandoval I., Wesseling S., Rietjens I.M.C.M. Occurrence and Probabilistic Risk Assessment of Fumonisin B1, Fumonisin B2 and Deoxynivalenol in Nixtamalized Maize in Mexico City. Toxins. 2020;12:644.

    Not in our library10.3390/toxins12100644

  51. 51.

    Zentai A., Szeitzné-Szabó M., Mihucz G., Szeli N., Szabó S., Kovács M. Occurrence and Risk Assessment of Fumonisin B1 and B2 Mycotoxins in Maize-Based Food Products in Hungary. Toxins. 2019;11:709.

    Not in our library10.3390/toxins11120709

  52. 52.

    Schertz H., Dänicke S., Frahm J., Schatzmayr D., Dohnal I., Bichl G., Schwartz-Zimmermann H.E., Colicchia S., Breves G., Teifke J.P., et al. Biomarker Evaluation and Toxic Effects of an Acute Oral and Systemic Fumonisin Exposure of Pigs with a Special Focus on Dietary Fumonisin Esterase Supplementation. Toxins. 2018;10:296.

    Not in our library10.3390/toxins10070296

  53. 53.

    Hannun Y.A., Obeid L.M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 2018;19:175-191.

    Not in our library10.1038/nrm.2017.107

  54. 54.

    Chen J., Wei Z., Wang Y., Long M., Wu W., Kuca K. Fumonisin B1: Mechanisms of toxicity and biological detoxification progress in animals. Food Chem. Toxicol. 2021;149:111977.

    Not in our library10.1016/j.fct.2021.111977

  55. 55.

    Wang E., Ross P.F., Wilson T.M., Riley R.T., Merrill J.A.H. Increases in Serum Sphingosine and Sphinganine and Decreases in Complex Sphingolipids in Ponies Given Feed Containing Fumonisins, Mycotoxins Produced by Fusarium moniliforme. J. Nutr. 1992;122:1706-1716.

    Not in our library10.1093/jn/122.8.1706

  56. 56.

    Wangia R.N., Githanga D.P., Xue K.S., Tang L., Anzala O.A., Wang J.-S. Validation of urinary sphingolipid metabolites as biomarker of effect for fumonisins exposure in Kenyan children. Biomarkers. 2019;24:379-388.

    Not in our library10.1080/1354750x.2019.1587510

  57. 57.

    Riley R.T., Merrill A.H. Ceramide synthase inhibition by fumonisins: A perfect storm of perturbed sphingolipid metabolism, signaling, and disease. J. Lipid Res. 2019;60:1183-1189.

    Not in our library10.1194/jlr.s093815

  58. 58.

    Cabello-Verrugio C., Simon F., Trollet C., Santibañez J.F. Oxidative Stress in Disease and Aging: Mechanisms and Therapies. Oxidative Med. Cell. Longev. 2017;2017:4310469.

    Not in our library10.1155/2017/4310469

  59. 59.

    Arumugam T., Pillay Y., Ghazi T., Nagiah S., Abdul N.S., Chuturgoon A.A. Fumonisin B1-induced oxidative stress triggers Nrf2-mediated antioxidant response in human hepatocellular carcinoma (HepG2) cells. Mycotoxin Res. 2019;35:99-109.

    Not in our library10.1007/s12550-018-0335-0

  60. 60.

    Wang X., Wu Q., Wan D., Liu Q., Chen D., Liu Z., Martínez-Larrañaga M.R., Martínez M.-A., Anadón A., Yuan Z. Fumonisins: Oxidative stress-mediated toxicity and metabolism In Vivo and In Vitro. Arch. Toxicol. 2016;90:81-101.

    Not in our library10.1007/s00204-015-1604-8

  61. 61.

    Stockmann-Juvala H., Mikkola J., Naarala J., Loikkanen J., Elovaara E., Savolainen K. Oxidative Stress Induced by Fumonisin B1in Continuous Human and Rodent Neural Cell Cultures. Free Radic. Res. 2004;38:933-942.

    Not in our library10.1080/10715760412331273205

  62. 62.

    Yuan Q., Jiang Y., Fan Y., Ma Y., Lei H., Su J. Fumonisin B1 Induces Oxidative Stress and Breaks Barrier Functions in Pig Iliac Endothelium Cells. Toxins. 2019;11:387.

    Not in our library10.3390/toxins11070387

  63. 63.

    Mobio T.A., Tavan E., Baudrimont I., Anane R., Carratù M., Sanni A., Gbeassor M.F., Shier T.W., Narbonne J.-F., Creppy E.E. Comparative study of the toxic effects of fumonisin B1 in rat C6 glioma cells and p53-null mouse embryo fibroblasts. Toxicology. 2003;183:65-75.

    Not in our library10.1016/s0300-483x(02)00441-9

  64. 64.

    Cheng Y., Ren X., Gowda A.S., Shan Y., Zhang L., Yuan Y.-S., Patel R., Wu H., Huber-Keener K., Yang J.W., et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis. 2013;4:e731.

    Not in our library10.1038/cddis.2013.254

  65. 65.

    Demirel G., Alpertunga B., Ozden S. Role of fumonisin B1 on DNA methylation changes in rat kidney and liver cells. Pharm. Biol. 2015;53:1302-1310.

    Not in our library10.3109/13880209.2014.976714

  66. 66.

    Arumugam T., Ghazi T., Chuturgoon A. Fumonisin B1 Epigenetically Regulates PTEN Expression and Modulates DNA Damage Checkpoint Regulation in HepG2 Liver Cells. Toxins. 2020;12:625.

    Not in our library10.3390/toxins12100625

  67. 67.

    Yu S., Jia B., Liu N., Yu D., Zhang S., Wu A. Fumonisin B1 triggers carcinogenesis via HDAC/PI3K/Akt signalling pathway in human esophageal epithelial cells. Sci. Total Environ. 2021;787:147405.

    Not in our library10.1016/j.scitotenv.2021.147405

  68. 68.

    Arumugam T., Ghazi T., Chuturgoon A.A. Fumonisin B1 alters global m6A RNA methylation and epigenetically regulates Keap1-Nrf2 signaling in human hepatoma (HepG2) cells. Arch. Toxicol. 2021;95:1367-1378.

    Not in our library10.1007/s00204-021-02986-5

  69. 69.

    Matsuzawa A., Ichijo H. Stress-Responsive Protein Kinases in Redox-Regulated Apoptosis Signaling. Antioxid. Redox Signal. 2005;7:472-481.

    Not in our library10.1089/ars.2005.7.472

  70. 70.

    Kim S.H., Singh M.P., Sharma C., Kang S.C. Fumonisin B1 actuates oxidative stress-associated colonic damage via apoptosis and autophagy activation in murine model. J. Biochem. Mol. Toxicol. 2018;32:e22161.

    Not in our library10.1002/jbt.22161

  71. 71.

    Li H., Wang M., Kang W., Lin Z., Gan F., Huang K. Non-cytotoxic dosage of fumonisin B1 aggravates ochratoxin A-induced nephrocytotoxicity and apoptosis via ROS-dependent JNK/MAPK signaling pathway. Toxicology. 2021;457:152802.

    Not in our library10.1016/j.tox.2021.152802

  72. 72.

    Khan R., Phulukdaree A., Chuturgoon A.A. Concentration-dependent effect of fumonisin B1 on apoptosis in oesophageal cancer cells. Hum. Exp. Toxicol. 2017;37:762-771.

    Not in our library10.1177/0960327117735570

  73. 73.

    Oakes S.A., Papa F.R. The Role of Endoplasmic Reticulum Stress in Human Pathology. Annu. Rev. Pathol. Mech. Dis. 2015;10:173-194.

    Not in our library10.1146/annurev-pathol-012513-104649

  74. 74.

    Hou L., Yuan X., Le G., Lin Z., Gan F., Li H., Huang K. Fumonisin B1 induces nephrotoxicity via autophagy mediated by mTORC1 instead of mTORC2 in human renal tubule epithelial cells. Food Chem. Toxicol. 2021;149:112037.

    Not in our library10.1016/j.fct.2021.112037

  75. 75.

    Yu S., Jia B., Liu N., Yu D., Wu A. Evaluation of the Individual and Combined Toxicity of Fumonisin Mycotoxins in Human Gastric Epithelial Cells. Int. J. Mol. Sci. 2020;21:5917.

    Not in our library10.3390/ijms21165917

  76. 76.

    Yu S., Jia B., Yang Y., Liu N., Wu A. Involvement of PERK-CHOP pathway in fumonisin B1- induced cytotoxicity in human gastric epithelial cells. Food Chem. Toxicol. 2019;136:111080.

    Not in our library10.1016/j.fct.2019.111080

  77. 77.

    Liu X., Zhang E., Yin S., Zhao C., Fan L., Hu H. Activation of the IRE1α Arm, but not the PERK Arm, of the Unfolded Protein Response Contributes to Fumonisin B1-Induced Hepatotoxicity. Toxins. 2020;12:55.

    Not in our library10.3390/toxins12010055

  78. 78.

    Dugyala R.R., Sharma R.P., Tsunoda M., Riley R.T. Tumor necrosis factor-alpha as a contributor in fumonisin B1 toxicity. J. Pharmacol. Exp. Ther. 1998;285:317-324.

    Not in our library

  79. 79.

    Mahmoodi M., Alizadeh A.M., Sohanaki H., Rezaei N., Amini-Najafi F., Khosravi A.R., Hosseini S.-K., Safari Z., Hydarnasab D., Khori V. Impact of fumonisin B1 on the production of inflammatory cytokines by gastric and colon cell lines. Iran. J. Allergy Asthma Immunol. 2012;11:165-173.

    Not in our library

  80. 80.

    Chen J., Yang S., Huang S., Yan R., Wang M., Chen S., Cai J., Long M., Li P. Transcriptome study reveals apoptosis of porcine kidney cells induced by fumonisin B1 via TNF signalling pathway. Food Chem. Toxicol. 2020;139:111274.

    Not in our library10.1016/j.fct.2020.111274

  81. 81.

    Régnier M., Gourbeyre P., Pinton P., Napper S., Laffite J., Cossalter A., Bailly J., Lippi Y., Bertrand-Michel J., Bracarense A.P.F., et al. Identification of Signaling Pathways Targeted by the Food Contaminant FB1: Transcriptome and Kinome Analysis of Samples from Pig Liver and Intestine. Mol. Nutr. Food Res. 2017;61.

    Not in our library10.1002/mnfr.201700433

  82. 82.

    Abbès S., Ben Salah-Abbès J., Jebali R., Ben Younes R., Oueslati R. Interaction of aflatoxin B1and fumonisin B1 in mice causes immunotoxicity and oxidative stress: Possible protective role using lactic acid bacteria. J. Immunotoxicol. 2016;13:46-54.

    Not in our library10.3109/1547691x.2014.997905

  83. 83.

    Keck B.B., Bodine A.B. The Effects of Fumonisin B1 on viability and mitogenic response of avian immune cells. Poult. Sci. 2006;85:1020-1024.

    Not in our library10.1093/ps/85.6.1020

  84. 84.

    Taranu I., Marin D.E., Bouhet S., Pascale F., Bailly J.-D., Miller J.D., Pinton P., Oswald I.P. Mycotoxin Fumonisin B1 Alters the Cytokine Profile and Decreases the Vaccinal Antibody Titer in Pigs. Toxicol. Sci. 2005;84:301-307.

    Not in our library10.1093/toxsci/kfi086

  85. 85.

    Stoev S.D., Gundasheva D., Zarkov I., Mircheva T., Zapryanova D., Denev S., Mitev Y., Daskalov H., Dutton M., Mwanza M., et al. Experimental mycotoxic nephropathy in pigs provoked by a mouldy diet containing ochratoxin A and fumonisin B1. Exp. Toxicol. Pathol. 2012;64:733-741.

    Not in our library10.1016/j.etp.2011.01.008

  86. 86.

    Li Y., Fan Y., Xia B., Xiao Q., Wang Q., Sun W., Zhang H., He C. The immunosuppressive characteristics of FB1 by inhibition of maturation and function of BMDCs. Int. Immunopharmacol. 2017;47:206-211.

    Not in our library10.1016/j.intimp.2017.03.031

  87. 87.

    Yao Z.G., Zhang X.H., Hua F., Wang J.L., Xing X., Yan X., Xing L.X. Effects of fumonisin B1 on HLA class I antigen presentation and processing pathway in GES-1 cells In Vitro. Hum. Exp. Toxicol. 2011;30:379-390.

    Not in our library10.1177/0960327110371812

  88. 88.

    Li Z., Cui J., Zhang X., Kang W. Aflatoxin G1 reduces the molecular expression of HLA-I, TAP-1 and LMP-2 of adult esophageal epithelial cells In Vitro. Toxicol. Lett. 2010;195:169-173.

    Not in our library10.1016/j.toxlet.2010.03.1118

  89. 89.

    Mary V.S., Theumer M.G., Arias S.L., Rubinstein H.R. Reactive oxygen species sources and biomolecular oxidative damage induced by aflatoxin B1 and fumonisin B1 in rat spleen mononuclear cells. Toxicology. 2012;302:299-307.

    Not in our library10.1016/j.tox.2012.08.012

  90. 90.

    Kachlek M., Szabó-Fodor J., Bodnár Z.B., Horvatovich K., Kovács M. Preliminary results on the interactive effects of deoxynivalenol, zearalenone and fumonisin B1 on porcine lymphocytes. Acta Vet. Hung. 2017;65:340-353.

    Not in our library10.1556/004.2017.033

  91. 91.

    Mwanza M., Kametler L., Bonai A., Rajli V., Kovacs M., Dutton M.F. The cytotoxic effect of fumonisin B1 and ochratoxin A on human and pig lymphocytes using the Methyl Thiazol Tetrazolium (MTT) assay. Mycotoxin Res. 2009;25:233-238.

    Not in our library10.1007/s12550-009-0033-z

  92. 92.

    Cheng Y.-H., Ding S.-T., Chang M.-H. Effect of fumonisins on macrophage immune functions and gene expression of cytokines in broilers. Arch. Anim. Nutr. 2006;60:267-276.

    Not in our library10.1080/17450390600785079

  93. 93.
    Susceptibility of Broiler Chickens to Coccidiosis When Fed Subclinical Doses of Deoxynivalenol and Fumonisins—Special Emphasis on the Immunological Response and the Mycotoxin Interaction · 2016
    Not checked
  94. 94.

    Pósa R., Magyar T., Stoev S.D., Glávits R., Donko T., Repa I., Kovács M. Use of Computed Tomography and Histopathologic Review for Lung Lesions Produced by the Interaction between Mycoplasma hyopneumoniaeand Fumonisin Mycotoxins in Pigs. Vet. Pathol. 2013;50:971-979.

    Not in our library10.1177/0300985813480510

  95. 95.

    Oswald I., Desautels C., Laffitte J., Fournout S., Peres S.Y., Odin M., Le Bars P., Le Bars J., Fairbrother J.M. Mycotoxin Fumonisin B 1 Increases Intestinal Colonization by Pathogenic Escherichia coli in Pigs. Appl. Environ. Microbiol. 2003;69:5870-5874.

    Not in our library10.1128/aem.69.10.5870-5874.2003

  96. 96.

    Burel C., Tanguy M., Guerre P., Boilletot E., Cariolet R., Queguiner M., Postollec G., Pinton P., Salvat G., Oswald I., et al. Effect of Low Dose of Fumonisins on Pig Health: Immune Status, Intestinal Microbiota and Sensitivity to Salmonella. Toxins. 2013;5:841-864.

    Not in our library10.3390/toxins5040841

  97. 97.

    Halloy D.J., Gustin P.G., Bouhet S., Oswald I. Oral exposure to culture material extract containing fumonisins predisposes swine to the development of pneumonitis caused by Pasteurellamultocida. Toxicology. 2005;213:34-44.

    Not in our library10.1016/j.tox.2005.05.012

  98. 98.

    Kovács M., Pósa R., Tuboly T., Donko T., Repa I., Tossenberger J., Szabó-Fodor J., Stoev S., Magyar T. Feed exposure to FB1 can aggravate pneumonic damages in pigs provoked by P. multocid a. Res. Vet. Sci. 2016;108:38-46.

    Not in our library10.1016/j.rvsc.2016.07.011

  99. 99.

    Meyer K., Mohr K., Bauer J., Horn P., Kovacs M. Residue formation of fumonisin B1 in porcine tissues. Food Addit. Contam. 2003;20:639-647.

    Not in our library10.1080/0265203031000119043

  100. 100.

    Enongene E., Sharma R., Bhandari N., Voss K., Riley R. Disruption of sphingolipid metabolism in small intestines, liver and kidney of mice dosed subcutaneously with fumonisin B1. Food Chem. Toxicol. 2000;38:793-799.

    Not in our library10.1016/s0278-6915(00)00065-x

  101. 101.

    Dassi M., Souto N.S., Braga A.C.M., Freitas M.L., Vasconcelos C., Oliveira M., Furian A.F. Effects of repeated fumonisin B1 exposure on markers of oxidative stress in liver, kidneys, and lungs of C57BL/6 mice. J. Environ. Sci. Health Part B. 2018;53:840-845.

    Not in our library10.1080/03601234.2018.1505258

  102. 102.

    Tardieu D., Auby A., Bluteau C., Bailly J.-D., Guerre P. Determination of Fumonisin B1 in animal tissues with immunoaffinity purification. J. Chromatogr. B. 2008;870:140-144.

    Not in our library10.1016/j.jchromb.2008.05.046

  103. 103.

    Loiseau N., Polizzi A., Dupuy A., Therville N., Rakotonirainy M., Loy J., Viadere J.-L., Cossalter A.-M., Bailly J.-D., Puel O., et al. New insights into the organ-specific adverse effects of fumonisin B1: Comparison between lung and liver. Arch. Toxicol. 2015;89:1619-1629.

    Not in our library10.1007/s00204-014-1323-6

  104. 104.

    Gelderblom W., Cawood M., Snyman S., Marasas W. Fumonisin B1 dosimetry in relation to cancer initiation in rat liver. Carcinogenesis. 1994;15:209-214.

    Not in our library10.1093/carcin/15.2.209

  105. 105.

    Ewuola E.O. Organ traits and histopathology of rabbits fed varied levels of dietary fumonisin B1. J. Anim. Physiol. Anim. Nutr. 2009;93:726-731.

    Not in our library10.1111/j.1439-0396.2008.00862.x

  106. 106.

    Sharma N., He Q., Sharma R.P. Amelioration of fumonisin B1 hepatotoxicity in mice by depletion of T cells with anti-Thy-1.2. Toxicology. 2006;223:191-201.

    Not in our library10.1016/j.tox.2006.03.021

  107. 107.

    Howard P.C., Eppley R.M., Stack M.E., Warbritton A., Voss K.A., Lorentzen R.J., Kovach R.M., Bucci T.J. Fumonisin b1 carcinogenicity in a two-year feeding study using F344 rats and B6C3F1 mice. Environ. Health Perspect. 2001;109(Suppl. 2):277-282.

    Not in our library10.1289/ehp.01109s2277

  108. 108.

    Burger H.-M., Abel S., Gelderblom W. Modulation of key lipid raft constituents in primary rat hepatocytes by fumonisin B1—Implications for cancer promotion in the liver. Food Chem. Toxicol. 2018;115:34-41.

    Not in our library10.1016/j.fct.2018.03.004

  109. 109.

    Riley R.T., Hinton D.M., Chamberlain W.J., Bacon C.W., Wang E., Merrill J.A.H., Voss K.A. Dietary Fumonisin B1 Induces Disruption of Sphingolipid Metabolism in Sprague-Dawley Rats: A New Mechanism of Nephrotoxicity. J. Nutr. 1994;124:594-603.

    Not in our library10.1093/jn/124.4.594

  110. 110.

    Szabó A., Fébel H., Ali O., Kovács M. Fumonisin B1 induced compositional modifications of the renal and hepatic membrane lipids in rats—Dose and exposure time dependence. Food Addit. Contam. Part A. 2019;36:1722-1739.

    Not in our library10.1080/19440049.2019.1652772

  111. 111.

    Bondy G., Barker M., Lombaert G., Armstrong C., Fernie S., Gurofsky S., Huzel V., Savard M., Curran I. A comparison of clinical, histopathological and cell-cycle markers in rats receiving the fungal toxins fumonisin B1 or fumonisin B2 by intraperitoneal injection. Food Chem. Toxicol. 2000;38:873-886.

    Not in our library10.1016/s0278-6915(00)00084-3

  112. 112.

    Szabó A., Szabó-Fodor J., Kachlek M., Mézes M., Balogh K., Glávits R., Ali O., Zeebone Y.Y., Kovács M. Dose and Exposure Time-Dependent Renal and Hepatic Effects of Intraperitoneally Administered Fumonisin B1 in Rats. Toxins. 2018;10:465.

    Not in our library10.3390/toxins10110465

  113. 113.

    Hannun Y.A., Obeid L. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008;9:139-150.

    Not in our library10.1038/nrm2329

  114. 114.

    Sancak D., Ozden S. Global histone modifications in Fumonisin B1 exposure in rat kidney epithelial cells. Toxicol. Vitr. 2015;29:1809-1815.

    Not in our library10.1016/j.tiv.2015.07.019

  115. 115.

    Lallès J.-P., Lessard M., Oswald I.P., David J.-C. Consumption of fumonisin B1 for 9 days induces stress proteins along the gastrointestinal tract of pigs. Toxicon. 2010;55:244-249.

    Not in our library10.1016/j.toxicon.2009.07.027

  116. 116.

    Cao C., Zhu X., Li X., Ouyang H., Wang K., Li X. Assessment of ionic homeostasis imbalance and cytochrome P450 system disturbance in mice during fumonisin B1 (FB1) exposure. Chemosphere. 2020;251:126393.

    Not in our library10.1016/j.chemosphere.2020.126393

  117. 117.

    Chen Z., Chen H., Li X., Yuan Q., Su J., Yang L., Ning L., Lei H. Fumonisin B1 damages the barrier functions of porcine intestinal epithelial cells In Vitro. J. Biochem. Mol. Toxicol. 2019;33:e22397.

    Not in our library10.1002/jbt.22397

  118. 118.

    Constable P.D., Smith G., Rottinghaus G.E., Haschek W.M. Ingestion of Fumonisin B1-Containing Culture Material Decreases Cardiac Contractility and Mechanical Efficiency in Swine. Toxicol. Appl. Pharmacol. 2000;162:151-160.

    Not in our library10.1006/taap.1999.8831

  119. 119.

    Come J., Cambaza E., Ferreira R., Da Costa J.M.C., Carrilho C. Esophageal cancer in Mozambique: Should mycotoxins be a concern? Pan Afr. Med. J. 2019;33:187.

    Not in our library10.11604/pamj.2019.33.187.18295

  120. 120.

    Constable P.D., Smith G., Rottinghaus G.E., Tumbleson M.E., Haschek W.M. Fumonisin-induced blockade of ceramide synthase in sphingolipid biosynthetic pathway alters aortic input impedance spectrum of pigs. Am. J. Physiol. Circ. Physiol. 2003;284:H2034-H2044.

    Not in our library10.1152/ajpheart.00155.2002

  121. 121.

    Hsiao S.-H., Constable P.D., Smith G., Haschek W.M. Effects of Exogenous Sphinganine, Sphingosine, and Sphingosine-1-Phosphate on Relaxation and Contraction of Porcine Thoracic Aortic and Pulmonary Arterial Rings. Toxicol. Sci. 2005;86:194-199.

    Not in our library10.1093/toxsci/kfi167

  122. 122.

    Mathur S., Constable P.D., Eppley R.M., Waggoner A.L., Tumbleson M.E., Haschek W.M. Fumonisin B1 Is Hepatotoxic and Nephrotoxic in Milk-Fed Calves. Toxicol. Sci. 2001;60:385-396.

    Not in our library10.1093/toxsci/60.2.385

  123. 123.

    Baker D.C., Rottinghaus G.E. Chronic Experimental Fumonisin Intoxication of Calves. J. Vet. Diagn. Investig. 1999;11:289-292.

    Not in our library10.1177/104063879901100315

  124. 124.

    Ali O., Szabó-Fodor J., Fébel H., Mézes M., Balogh K., Glávits R., Kovács M., Zantomasi A., Szabó A. Porcine Hepatic Response to Fumonisin B1 in a Short Exposure Period: Fatty Acid Profile and Clinical Investigations. Toxins. 2019;11:655.

    Not in our library10.3390/toxins11110655

  125. 125.

    Smith G., Constable P.D., Eppley R.M., Tumbleson M.E., Gumprecht L.A., Haschek-Hock W.M. Purified fumonisin B(1) decreases cardiovascular function but does not alter pulmonary capillary permeability in swine. Toxicol. Sci. 2000;56:240-249.

    Not in our library10.1093/toxsci/56.1.240

  126. 126.

    Haschek W.M., Gumprecht L.A., Smith G., Tumbleson M.E., Constable P.D. Fumonisin toxicosis in swine: An overview of porcine pulmonary edema and current perspectives. Environ. Health Perspect. 2001;109(Suppl. 2):251-257.

    Not in our library10.1289/ehp.01109s2251

  127. 127.

    Salam G.A., Mehlab E., El-Shishtawy M. Fumonisin Lung Toxicity: Gross and Microscopic Changes are Dose and Time Dependent. J. Am. Sci. 2012;8:729-736.

    Not in our library

  128. 128.

    Hard G.C., Howard P.C., Kovatch R.M., Bucci T.J. Rat Kidney Pathology Induced by Chronic Exposure to Fumonisin B1 Includes Rare Variants of Renal Tubule Tumor. Toxicol. Pathol. 2001;29:379-386.

    Not in our library10.1080/019262301316905345

  129. 129.

    Howard P.C., Warbritton A., Voss K.A., Lorentzen R.J., Thurman J.D., Kovach R.M., Bucci T.J. Compensatory regeneration as a mechanism for renal tubule carcinogenesis of fumonisin B1 in the F344/N/Nctr BR rat. Environ. Health Perspect. 2001;109(Suppl. 2):309-314.

    Not in our library10.1289/ehp.01109s2309

  130. 130.

    Smith G., Constable P.D., Foreman J.H., Eppley R.M., Waggoner A.L., Tumbleson M.E., Haschek W.M. Cardiovascular changes associated with intravenous administration of fumonisin B1 in horses. Am. J. Vet. Res. 2002;63:538-545.

    Not in our library10.2460/ajvr.2002.63.538

  131. 131.

    Orsi R., Oliveira C., Dilkin P., Xavier J., Direito G., Corrêa B. Effects of oral administration of aflatoxin B1 and fumonisin B1 in rabbits (Oryctolagus cuniculus). Chem. Interact. 2007;170:201-208.

    Not in our library10.1016/j.cbi.2007.08.002

  132. 132.

    Sharma D., Asrani R.K., LeDoux D.R., Rottinghaus G.E., Gupta V.K. Toxic Interaction between Fumonisin B1 and Moniliformin for Cardiac Lesions in Japanese Quail. Avian Dis. 2012;56:545-554.

    Not in our library10.1637/10036-121111-reg.1

  133. 133.

    Foreman J.H., Constable P.D., Waggoner A.L., Lévy M., Eppley R., Smith G.W., Tumbleson M.E., Haschek W.M. Neurologic Abnormalities and Cerebrospinal Fluid Changes in Horses Administered Fumonisin B1 Intravenously. J. Vet. Intern. Med. 2004;18:223-230.

    Not in our library10.1111/j.1939-1676.2004.tb00165.x

  134. 134.

    Banczerowski-Pelyhe I., Détári L., Világi I., Al E. Nerve conduction velocity and spinal reflexes may change in rats after fumonisin B1 exposure. Acta Biol. Hung. 2002;53:413-422.

    Not in our library10.1556/abiol.53.2002.4.3

  135. 135.

    Sandmeyer L.S., Vujanovic V., Petrie L., Campbell J.R., Bauer B.S., Allen A.L., Grahn B.H. Optic neuropathy in a herd of beef cattle in Alberta associated with consumption of moldy corn. Can. Vet. J. 2015;56:249-256.

    Not in our library

  136. 136.

    Kovacic S., Pepeljnjak S., Petrinec Z., Klarić M. Fumonisin B1 Neurotoxicity in Young Carp (Cyprinus Carpio L.). Arch. Ind. Hyg. Toxicol. 2009;60:419-426.

    Not in our library10.2478/10004-1254-60-2009-1974

  137. 137.

    Marasas W.F.O., Riley R.T., Hendricks K.A., Stevens V.L., Sadler T.W., Waes J.G.-V., Missmer S.A., Cabrera J., Torres O., Gelderblom W.C.A., et al. Fumonisins Disrupt Sphingolipid Metabolism, Folate Transport, and Neural Tube Development in Embryo Culture and In Vivo: A Potential Risk Factor for Human Neural Tube Defects among Populations Consuming Fumonisin-Contaminated Maize. J. Nutr. 2004;134:711-716.

    Not in our library10.1093/jn/134.4.711

  138. 138.

    Voss K.A., Riley R.T., Waes J.G.-V. Fumonisin B1 induced neural tube defects were not increased in LM/Bc mice fed folate-deficient diet. Mol. Nutr. Food Res. 2014;58:1190-1198.

    Not in our library10.1002/mnfr.201300720

  139. 139.

    Kigen G., Busakhala N., Kamuren Z., Rono H., Kimalat W., Njiru E. Factors associated with the high prevalence of oesophageal cancer in Western Kenya: A review. Infect. Agents Cancer. 2017;12:59.

    Not in our library10.1186/s13027-017-0169-y

  140. 140.

    Xue K.S., Tang L., Sun G., Wang S., Hu X., Wang J.-S. Mycotoxin exposure is associated with increased risk of esophageal squamous cell carcinoma in Huaian area, China. BMC Cancer. 2019;2019:1218.

    Not in our library10.1186/s12885-019-6439-x

  141. 141.

    Wang S.-K., Wang T.-T., Huang G.-L., Shi R.-F., Yang L.-G., Sun G.-J. Stimulation of the proliferation of human normal esophageal epithelial cells by fumonisin B1 and its mechanism. Exp. Ther. Med. 2014;7:55-60.

    Not in our library10.3892/etm.2013.1364

  142. 142.

    Lin D.-C., Shi Z.-Z., Xue L.-Y., Chen W., Xu X., Han Y.-L., Lv N., Wang M.-R. Expression of cell cycle related proteins cyclin D1, p53 and p21WAF1/Cip1 in esophageal squamous cell carcinoma. Hereditas. 2010;32:455-460.

    Not in our library10.3724/sp.j.1005.2010.00455

  143. 143.

    Myburg R.B., Dutton M.F., Chuturgoon A.A. Cytotoxicity of fumonisin B1, diethylnitrosamine, and catechol on the SNO esophageal cancer cell line. Environ. Health Perspect. 2002;110:813-815.

    Not in our library10.1289/ehp.02110813

  144. 144.

    Minervini F., Garbetta A., D’Antuono I., Cardinali A., Martino N.A., Debellis L., Visconti A. Toxic Mechanisms Induced by Fumonisin B1 Mycotoxin on Human Intestinal Cell Line. Arch. Environ. Contam. Toxicol. 2014;67:115-123.

    Not in our library10.1007/s00244-014-0004-z

  145. 145.

    Wang S.-K., Liu S., Yang L.-G., Shi R.-F., Sun G.-J. Effect of fumonisin B1 on the cell cycle of normal human liver cells. Mol. Med. Rep. 2013;7:1970-1976.

    Not in our library10.3892/mmr.2013.1447

  146. 146.

    Chuturgoon A.A., Phulukdaree A., Moodley D. Fumonisin B1 modulates expression of human cytochrome P450 1b1 in human hepatoma (Hepg2) cells by repressing Mir-27b. Toxicol. Lett. 2014;227:50-55.

    Not in our library10.1016/j.toxlet.2014.02.026

  147. 147.

    Persson E.C., Sewram V., Evans A.A., London W.T., Volkwyn Y., Shen Y.-J., Van Zyl J.A., Chen G., Lin W., Shephard G.S., et al. Fumonisin B1 and risk of hepatocellular carcinoma in two Chinese cohorts. Food Chem. Toxicol. 2012;50:679-683.

    Not in our library10.1016/j.fct.2011.11.029

  148. 148.

    Tolleson W.H., Dooley K.L., Sheldon W.G., Thurman J.D., Bucci T.J., Howard P.C. The Mycotoxin Fumonisin Induces Apoptosis in Cultured Human Cells and in Livers and Kidneys of Rats. Fumonisins in Food. 1996;392:237-250.

    Not in our library10.1007/978-1-4899-1379-1_21

  149. 149.

    Sharma N., He Q., Sharma R.P. Sphingosine kinase activity confers resistance to apoptosis by fumonisin B1 in human embryonic kidney (HEK-293) cells. Chem. Interact. 2004;151:33-42.

    Not in our library10.1016/j.cbi.2004.10.003

  150. 150.

    Seefelder W., Humpf H.-U., Schwerdt G., Freudinger R., Gekle M. Induction of apoptosis in cultured human proximal tubule cells by fumonisins and fumonisin metabolites. Toxicol. Appl. Pharmacol. 2003;192:146-153.

    Not in our library10.1016/s0041-008x(03)00262-x

  151. 151.

    Tolleson W.H., Couch L.H., Melchior W.B., Jenkins G.R., Muskhelishvili M., Muskhelishvili L., McGarrity L.J., Domon O., Morris S.M., Howard P.C. Fumonisin B1 induces apoptosis in cultured human keratinocytes through sphinganine accumulation and ceramide depletion. Int. J. Oncol. 1999;14:833-843.

    Not in our library10.3892/ijo.14.5.833

  152. 152.

    Tolleson W.H., Melchior W.B., Morris S.M., McGarrity L.J., Domon O.E., Muskhelishvili L., James S., Howard P.C. Apoptotic and anti-proliferative effects of fumonisin B1 in human keratinocytes, fibroblasts, esophageal epithelial cells and hepatoma cells. Carcinogenesis. 1996;17:239-249.

    Not in our library10.1093/carcin/17.2.239

  153. 153.

    Abdel-Wahhab M.A., Hassan A.M., Amer H.A., Naguib K.M. Prevention of fumonisin-induced maternal and developmental toxicity in rats by certain plant extracts. J. Appl. Toxicol. 2004;24:469-474.

    Not in our library10.1002/jat.1000

  154. 154.

    Somoskői B., Kovács M., Cseh S. Effects of T-2 and Fumonisin B1 combined treatment on in vitro mouse embryo development and blastocyst quality. Toxicol. Ind. Health. 2018;34:353-360.

    Not in our library10.1177/0748233718764039

  155. 155.

    Li W., Zhao H., Zhuang R., Wang Y., Cao W., He Y., Jiang Y., Rui R., Ju S. Fumonisin B1 exposure adversely affects porcine oocyte maturation in vitro by inducing mitochondrial dysfunction and oxidative stress. Theriogenology. 2021;164:1-11.

    Not in our library10.1016/j.theriogenology.2021.01.011

  156. 156.

    Lumsangkul C., Chiang H.-I., Lo N.-W., Fan Y.-K., Ju J.-C. Developmental Toxicity of Mycotoxin Fumonisin B1 in Animal Embryogenesis: An Overview. Toxins. 2019;11:114.

    Not in our library10.3390/toxins11020114

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.